药明康德：出售附属公司交易已完成交割

Core Viewpoint - WuXi AppTec announced that its subsidiary, Shanghai WuXi, has received the first installment of the transfer price amounting to RMB 1.54 billion from Hillhouse Capital, completing the equity transfer agreement and meeting the necessary conditions for delivery [1] Group 1 - The equity transfer agreement has been successfully executed, resulting in the exclusion of Kangde Hongyi and Jinshi Pharmaceutical from the company's consolidated financial statements [1] - The transaction is expected to generate an after-tax net profit of approximately RMB 960 million, which represents over 10% of the company's most recent audited net profit attributable to shareholders for the fiscal year 2024 [1]